IL6 and COVID-19: As a matter of fact, in our patients’ cohort, D-dimers, IL-6, procalcitonin, and CRP were found to be significantly higher (p < 0.001) in non-survivors compared with surviving patients, which highlights the effect of increased inflammation and thromboembolic complications on the medium-term mortality of COVID-19 patients.